Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

miRNA-28 compound as chronic pain marker and application of compound in preparation of medicine for treating chronic pain

A technology of 1. mirna-28 and 2. mirna-28, which is applied in the field of biomedical materials and can solve problems such as unreported uses

Inactive Publication Date: 2014-11-19
XUZHOU MEDICAL COLLEGE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The use of miRNA-28 as a gene to suppress chronic pain and as a marker for chronic pain diagnosis has not been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • miRNA-28 compound as chronic pain marker and application of compound in preparation of medicine for treating chronic pain
  • miRNA-28 compound as chronic pain marker and application of compound in preparation of medicine for treating chronic pain
  • miRNA-28 compound as chronic pain marker and application of compound in preparation of medicine for treating chronic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] 1. Preparation of CFA chronic arthritis pain model:

[0021] SPF male SD rats (250 g-270 g) were anesthetized with isoflurane, and subcutaneously injected 100 microliters of CFA into the soles of the left hind limbs, and adult mice (23-28 g) were subcutaneously injected with 20 microliters of CFA in the soles of the left hind limbs. For juvenile rats (9-14 days), inject 40 microliters of CFA into both hind limbs respectively. Since the immune system of newborn rats is not fully developed, the inflammation of the hind limbs will disappear after 2 days, so 20 microliters of CFA will be injected after 2 days. The inflammatory pain produced in this way can last at least 4 days. All the above control groups were injected with 0.9% normal saline. Because animals respond most strongly to thermal or mechanical stimuli 3 days after CFA injection, this time was used as a persistent inflammatory pain model.

[0022] 2. Pain behavior monitoring:

[0023] a. Mechanical allodynia:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biotechnology and medicines and relates to use of a gene miRNA-28 in treatment of chronic pain. Down-regulated expression of the miRNA-28 in blood of a patient with chronic pain is verified for the first time, and the miRNA-28 can directly regulate Nnat-mediated calcium ion signal channel in occurrence of chronic pan and can remarkably inhibit occurrence and formation of the chronic pan. A clinical specimen of blood of the patient with chronic pain is further quantitatively analyzed, representing that the miRNA-28 can be used as the marker for occurrence of chronic pain.

Description

technical field [0001] The invention relates to the application of a microRNA molecule, in particular to the application of miRNA-28, specifically the application of the miRNA-28 compound as a marker of chronic pain and in the preparation of drugs for treating chronic pain, and belongs to the technical field of biomedical materials. Background technique [0002] Chronic pain is one of the most common clinical diseases with high incidence. According to statistics, there are as many as 320 million patients with chronic pain worldwide. Chronic pain can be caused by injury or trauma, infection, and inflammation of the central nervous system (CNS) or peripheral nervous system (PNS). The main clinical manifestations are spontaneous pain, hyperalgesia, and allodynia. Due to the complex etiology and unclear pathogenesis, the treatment is very difficult. Patients with long-term chronic pain are prone to symptoms such as anxiety, depression, and insomnia, and consume a lot of medical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68A61K48/00A61P29/00A61P25/04
CPCC12Q1/6883A61K31/713C12N15/113C12N2310/141C12Q2600/158C12Q2600/178
Inventor 李燕强曹君利潘志强
Owner XUZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com